Two major developments in AI-driven drug discovery reveal how pharmaceutical research is moving beyond experimental pilots toward structured, scalable approaches. The University of Oxford's Nuffield Department of Medicine has partnered with 2U to launch the Oxford AI in Drug Discovery and Medicine Programme, a six-week online executive education course designed to equip scientists and R&D professionals with practical skills in applying artificial intelligence across the drug discovery pipeline. Simultaneously, Japanese pharmaceutical company Ono Pharma has entered a partnership with Aitia, a Cambridge-based AI firm, to use causal AI technology to identify new therapeutic targets in neurological diseases.

Why Are Universities and Pharma Companies Investing in AI Drug Discovery Training?

The Oxford program addresses a critical gap in the pharmaceutical workforce. While AI tools are becoming more powerful, many researchers lack the knowledge to apply them effectively within the scientific, ethical, and regulatory context of modern medicine. The curriculum is designed for professionals who need to understand and deploy AI in biomedical research without requiring prior coding experience. The program covers how AI can support target identification, biomarker discovery, patient stratification, and therapeutic prediction, using industry tools including MedChemica and Target Safety.

The partnership reflects a broader trend: universities are extending their expertise into fields where AI and healthcare advances are reshaping professional practice. Andy Morgan, Chief Partnerships Officer at 2U, noted that the collaboration with Oxford represents momentum across multiple disciplines. The Nuffield Department of Medicine partnership is part of 2U's growing relationship with Oxford, which now spans more than 40 online executive education programs and open courses delivered through edX, bringing together leading Oxford schools including Saïd Business School, the Faculty of Law, and the Blavatnik School of Government.

What Makes Causal AI Different From Conventional AI in Drug Discovery?

Ono Pharma's partnership with Aitia highlights an emerging distinction in AI drug discovery technology. Rather than relying solely on pattern recognition, causal AI aims to uncover the underlying mechanisms driving disease. Aitia will use its REFS technology to build what it calls Gemini Digital Twins (GDTs) of neurological diseases, identifying new therapeutic targets and biomarkers that conventional AI approaches might miss. This matters because neurological diseases have complex, incompletely understood mechanisms, making it difficult to identify true therapeutic targets using traditional methods.

"We are delighted to leverage cutting-edge REFS technology to identify true therapeutic targets in neurological diseases, where disease mechanisms are complex and not yet fully understood. We believe this will accelerate the development of innovative medicines," said Seishi Katsumata, Corporate Officer and Executive Vice President of Discovery and Research at Ono.

Seishi Katsumata, Corporate Officer and Executive Vice President of Discovery and Research, Ono Pharmaceutical

Colin Hill, CEO and co-founder of Aitia, emphasized the advantage of causal reasoning over conventional AI. He stated that the partnership will help uncover disease mechanisms and therapeutic targets that could not be identified with conventional AI, thereby accelerating the development of new therapies. Under the agreement, Ono will have an exclusive worldwide option right to research, develop, and commercialize drug candidates to the targets identified by Aitia.

How Are Leading Institutions Preparing the Next Generation of AI Drug Researchers?

The Oxford program combines technical training with ethical and regulatory education, reflecting the maturation of AI in pharma. Participants explore practical applications while also examining the ethical, legal, and regulatory considerations surrounding AI in medicine. Key topics include:

• Algorithmic Bias: Understanding how AI models can inadvertently perpetuate or amplify biases in medical data and how to mitigate these risks.
• Model Explainability: Learning how to interpret and explain AI predictions so that researchers and clinicians can understand why a model recommends a particular therapeutic target or biomarker.
• Responsible Deployment: Navigating the regulatory landscape and ensuring that AI-driven discoveries meet the standards required for clinical development and approval.

The program was developed by faculty with a track record in open-science research, including researchers who led open-science initiatives during the COVID-19 pandemic and contributed to OpenBind, an open-science consortium building the world's largest public dataset linking protein structures to binding measurements. Participants complete practical assessments throughout the six-week course, culminating in an AI implementation roadmap they can apply within their own organizations.

Dr. Abigail Rickard, Head of Academic Programmes at the Nuffield Department of Medicine, explained the rationale behind the program. She stated that artificial intelligence is creating new opportunities to accelerate biomedical discovery, but realizing its full potential requires scientists who understand not only the technology but also the scientific, ethical, and regulatory context in which it is applied.

"This program combines our expertise in biomedical research with practical applications of AI, giving professionals the knowledge and tools to translate emerging technologies into meaningful advances in drug discovery and medicine," said Dr. Abigail Rickard.

Dr. Abigail Rickard, Head of Academic Programmes, Nuffield Department of Medicine, University of Oxford

The timing of these initiatives reflects a shift in how the pharmaceutical industry views AI. Rather than treating it as a speculative technology, companies and academic institutions are now building structured pathways to integrate AI into existing drug discovery workflows. The Oxford program is expected to launch soon, while Ono Pharma's partnership with Aitia is already underway, with the company having exclusive rights to develop drugs based on targets identified through the causal AI analysis. A second executive education offering from the Nuffield Department of Medicine, the Oxford Nuffield Healthcare Management Programme, is expected to launch later in 2026, further extending the collaboration into life sciences and healthcare.